ArticleClinical and translational allergy2026
Between Guidelines and Daily Practice: The Persistent Use of Parenteral Depot Corticosteroids in Germany.
Article in Clinical and translational allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundParenteral depot corticosteroids (PDCs) continue to be prescribed for allergic and respiratory diseases, despite clear guideline recommendations against their use. This clinical practice raises significant safety concerns. We analyzed current PDC use in Germany and characterized prescribing patterns.
methodsRetrospective analysis of anonymized, longitudinal prescription data (IQVIA LRx) and evaluation of anonymized electronic medical record (EMR) data (IQVIA Disease Analyzer) from October 2023 to September 2024. Data were stratified by diagnosis, prescription frequency, prescriber specialty, region, age group and comorbidities.
resultsThe analysis of prescription data revealed that 9984 asthma and 5279 chronic obstructive pulmonary disease (COPD) patients received at least one PDC injection annually by general practitioners, which are the predominant prescribers. Of these patients, the majority received a single prescription. Regional differences were observed with particularly high prescription rates in western regions such as Rhineland-Palatinate and Saarland. Monthly PDC prescription rates follow seasonal patterns of most common pollen allergens. Furthermore, over 23,000 patients with rhinopathy but without asthma or COPD received at least one prescription as well as approximately 3700 patients with chronic sinusitis with or without nasal polyps but no asthma or COPD.
conclusionPDCs continue to be administered to a relevant number of patients with asthma, COPD, and upper airway diseases despite clear guideline recommendations against systemic steroid treatment. The injection frequency, as well as the association with allergic comorbidities and seasonal patterns are compatible with the treatment of seasonal allergies. This underscores the need for targeted educational initiatives and stronger implementation of guideline-adherent therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.